Emergent BioSolutions (EBS) Tops Q3 EPS by 27c
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.68, $0.27 better than the analyst estimate of $0.41. Revenue for the quarter came in at $149.4 million versus the consensus estimate of $124.55 million.
Full Year 2017 Forecast
Full Year 2017 Forecast
Taking into account the year-to-date performance as well as our recent acquisitions and other news flow, the company is raising its financial forecast for the full year to reflect the strength of the company’s operations.
| (in millions) | Previous | ||
| $540 to $560 | BioThrax® | $265 to $280 | |
| $70 to $80 | Adjusted Net Income (1) | $70 to $80 | |
| $150 to $160 | $135 to $145 |
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.